Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ≥ 12 to ≤ 80 years of age~* Diagnosis of homozygous familial hypercholesterolemia~* Stable lipid-lowering therapies for at least 4 weeks~* LDL cholesterol ≥ 130 mg/dl (3.4 mmol/L)~* Triglyceride ≤ 400 mg/dL (4.5 mmol/L)~* Bodyweight of ≥ 40 kg at screening.~Exclusion Criteria:~* LDL or plasma apheresis within 8 weeks prior to randomization~* New York Heart Association (NYHA) class III or IV or last known left ventricular ejection fraction \< 30%~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of randomization~* Planned cardiac surgery or revascularization~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Evolocumab (Type: EXPERIMENTAL): Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
- Part B: Evolocumab (Type: EXPERIMENTAL): Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
- Part B: Placebo (Type: PLACEBO_COMPARATOR): Participants received double-blind placebo subcutaneously once a month for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).